Aeterna Zentaris to Present Proof of Concept for Disorazol Z Cytotoxic
Conjugates such as AEZS-125 in Ovarian Cancer Mouse Model at Upcoming ENA
QUÉBEC CITY, Nov. 1, 2012
QUÉBEC CITY, Nov. 1, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX:AEZ) (the"Company") today announced that its Director of Preclinical
Development, Babette Aicher, PhD, will be making a poster presentation on
preclinical results for disorazol Z cytotoxic conjugates, such as AEZS-125, in
ovarian cancer, at the upcoming 24^th EORTC-NCI-AACR (ENA) Symposium on
"Molecular Targets and Cancer Therapeutics", which will be held November 6-9,
2012 in Dublin, Ireland. The study is funded through a grant from the German
Ministry of Education and Research.
Abstract #330: "Highly Potent Cytotoxic Conjugates of Disorazol Z Linked to a
LHRH-Receptor Targeting Peptide, such as AEZS-125, Interfere
with Cell Cycle Progression in Human Cancer Cell Lines and
Suppress Tumor Growth in a LHRH Receptor Positive Ovarian
Cancer Xenograft Model ", B. Aicher, T. Schuster, L.
Blumenstein, P. Schmidt, H. Irschik, R. Jansen, R. Mueller,
E.Guenther, M. Teifel.
Session: Monoclonal Antibodies and Targeted Toxins/Nuclides
Poster Board: 080
Date& Time: Thursday, November 8, 2012, from 12 noon to 2:15 pm (local
Venue: Convention Centre Dublin
About Disorazol Z cytotoxic conjugate, AEZS-125
AEZS-125 is a disorazol Z (AEZS-137) cytotoxic conjugate linked to a
Luteinizing Hormone-Releasing Hormone (LHRH)-receptor targeting peptide.
Disorazol Z is a novel natural compound isolated from myxobacterium Soranglium
cellulosumwith outstanding cytotoxic activity. Disorazol Z is a macrocyclic
polyketide which is available via fermentation in high yield and purity.
Besides tubulin binding, disorazol Z has pro-apoptotic properties and arrested
cancer cells in G2 stage of the cell cycle at subnanomolar concentrations.
Disorazol Z is an ideal partner for the formation of cytotoxic conjugates with
peptides and proteins to selectively target cancer cells.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development company
currently investigating treatments for various unmet medical needs. The
Company's pipeline encompasses compounds at all stages of development, from
drug discovery through to marketed products. For more information please visit
SOURCE AETERNA ZENTARIS INC.
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406
Press spacebar to pause and continue. Press esc to stop.